Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO
29 Dicembre 2022 - 12:00AM
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the
Company), a women's health company focused on the treatment of
Abnormal Uterine Bleeding (AUB), announced today that David
Clapper, who has served as President and Chief Executive Officer
since 2011, has chosen to retire. The Company’s board of directors
(the Board) has appointed industry executive Todd Usen as President
and Chief Executive Officer of Minerva Surgical and a member of the
Board to succeed Mr. Clapper effective January 2, 2023. To ensure a
smooth leadership transition, Mr. Clapper will continue to serve in
his role through Mr. Usen’s first day of employment and has
entered into a consulting agreement for 12 months following his
retirement.
“On behalf of the Board, the management team, and Minerva
Surgical’s employees, we want to thank Dave for his leadership and
impact over the last eleven years, building a leading business in
women’s health,” said Ross Jaffe, M.D, Minerva Surgical’s Chairman
of the Board. “We appreciate Dave securing our latest financing as
well as assisting in the search to find a strong successor, both of
which ensure that Minerva Surgical is well-positioned going
forward.”
Dr. Jaffe continued, “We are delighted to welcome Todd Usen to
his new role as President and Chief Executive Officer of Minerva
Surgical. Todd’s experience leading best-in-class medical device
companies and driving market growth is a great strategic fit for
the Company. The Board and management team look forward to working
with him to continue to improve patient lives and grow our
outstanding women’s health company.”
“It’s been a great privilege to collaborate with our incredible
team to serve Minerva Surgical’s stockholders, customers, and
employees, and I am so proud of what we’ve accomplished together,”
said Mr. Clapper. “I have served over eleven years as CEO, and I
feel this is the right time for me to step aside and start a new
chapter in my life. Minerva Surgical is in a great operational
position and is led by an experienced management team. I have the
utmost confidence in Todd to lead Minerva Surgical into the future
and fulfill the mission to meet the uterine health needs of
women.”
“I am honored to join Minerva Surgical and look forward to
working with the entire organization to continue driving value for
all stakeholders, but most importantly women all over the world who
experience heavy bleeding, leading to unnecessary hysterectomies,”
said Mr. Usen. “With the most convincing clinical data in the
market, a strong commercial footprint and the recently announced
financing, I believe that Minerva Surgical is poised to scale our
growth and deliver best-in-class surgical solutions to better serve
the compelling unmet needs in women’s health today.”
Mr. Usen has extensive commercial and operational experience
with a proven track record of leading large, complex global
businesses across several highly-regarded medical device companies.
He most recently spent the last four years as the Chief Executive
Officer of Activ Surgical, a digital surgery company focused on
advanced surgical imaging and AI, where he oversaw the FDA/CE
clearance of its ActivSight technology, as well as leading four
fundraising rounds totaling over $92 million. From 2015 to 2018,
Mr. Usen was President, Medical Systems Group, for Olympus
Corporation of the Americas, where he took charge of a complex $2B+
business and restructured the company for leaner growth and
investment, drove successful mergers and acquisitions activity, led
the expansion from 6 medical divisions to 11 in 3.5 years. Prior to
that, Mr. Usen served in executive positions including President,
United States Orthopedics, Senior Vice President & General
Manager, Joint Reconstruction, and Senior Vice President Sports
Medicine at Smith and Nephew, and Vice President Sales and Director
of Sales at Boston Scientific Corporation. Mr. Usen holds a BS in
Marketing from the Isenberg School at the University of
Massachusetts.
About Minerva Surgical, Inc.
Minerva Surgical is a commercial-stage medical technology
company focused on developing, manufacturing, and commercializing
minimally invasive solutions to meet the distinct uterine
healthcare needs of women. The Company has established a broad
product line of commercially available, minimally invasive
alternatives to hysterectomy, which are designed to address the
most common causes of Abnormal Uterine Bleeding (AUB) in most
uterine anatomies. The Minerva Surgical solutions can be used in a
variety of medical treatment settings and aim to address the
drawbacks associated with alternative treatment methods and to
preserve the uterus by avoiding unnecessary hysterectomies.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements are based on management’s
current assumptions and expectations of future events and trends,
which affect or may affect the Company’s business, strategy,
operations or financial performance, and actual results may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements may
include, but are not limited to, statements regarding plans for
David Clapper to retire and Todd Usen to join the Company.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Actual results may differ materially from these statements and from
actual or future events due to a variety of factors. Other factors
that could cause actual results to differ materially from those
contemplated in this press release can be found in the Risk Factors
section of the Company’s most recent quarterly report on Form 10-Q
for the quarter ended September 30, 2022, as filed with the SEC on
November 14, 2022, and available at www.SEC.gov. Because
forward-looking statements are inherently subject to risks and
uncertainties, you should not rely on these forward-looking
statements as predictions of future events. All statements other
than statements of historical fact are forward-looking statements.
Except to the extent required by law, the Company undertakes no
obligation to update or review any estimate, projection, or
forward-looking statement. Actual results may differ from those set
forth in this press release due to the risks and uncertainties
inherent in the Company’s business.
MEDIA CONTACT
Mike Clappermike.clapper@minervasurgical.com 804-295-7676
INVESTOR RELATIONS CONTACT
Caroline Cornerinvestors@minervasurgical.com415-202-5678
RELATED LINKS
https://www.aubandme.com
https://www.minervasurgical.com
Grafico Azioni Minerva Surgical (NASDAQ:UTRS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Minerva Surgical (NASDAQ:UTRS)
Storico
Da Giu 2023 a Giu 2024